1994
DOI: 10.1016/0958-3947(94)90083-3
|View full text |Cite
|
Sign up to set email alerts
|

Results of ruthenium irradiation of uveal melanoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

1996
1996
2014
2014

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…Some claim that 75"/0 of patients that have ruthenium plaque radiotherapy for posterior uveal melanoma retain useful vision (Guthoff et al 1986;Tjho-Heslinga et al 1993), or that pre-treatment visual acuity is preserved in 72% of patients (Muller et al 1986). However, to compare the visual outcome in different groups of patients receiving plaque radiotherapy is exceedingly difficult.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Some claim that 75"/0 of patients that have ruthenium plaque radiotherapy for posterior uveal melanoma retain useful vision (Guthoff et al 1986;Tjho-Heslinga et al 1993), or that pre-treatment visual acuity is preserved in 72% of patients (Muller et al 1986). However, to compare the visual outcome in different groups of patients receiving plaque radiotherapy is exceedingly difficult.…”
Section: Discussionmentioning
confidence: 99%
“…Ruthenium plaque radiotherapy for posterior uveal melanoma was conceptualized in the 1960s and subsequently popularized by Lommatzsch (Lommatzsch & Vollmar 1966;Lommatzsch 1986). Since then, brachytherapy using ruthenium 106 has been adopted by a large number of ocular oncology centres (Guthoff et al 1986;Miiller et al 1986;Shields et al 1989;Grange et al 1990;Bacin et al 1991;Summanen et al 1993;Tjho-Heslinga et al 1993;Kleineidam et al 1993). In Sweden, ruthenium plaque radiotherapy was introduced in 1979 and the facilities have remained confined to one centre.…”
mentioning
confidence: 99%
“…Malignant choroidal melanomas are today to a great extent treated by various irradiation methods (Finger et al 1989;Char 1989;Abrahamson et al 1992). The recurrence may be difficult to disclose because of a large variation in tumour response upon treatment Tjho-Heslinga et al 1993). Thus it is of great importance to use methods with high accuracy and with little or no discomfort or danger to the patient.…”
Section: Discussionmentioning
confidence: 99%
“…Once dose rates fall-off rapidly in the more distant structures from the applicator, due to the limited range of the electrons in tissue, there is a limitation of tumors size that are able to be reasonably treated with such applicators; justifying the important therapeutic indication of the 106 Ru/ 106 Rh applicators for small and medium tumors. 3,5,7,8,9 Discussion and Conclusions…”
Section: Dose Distribution In the Eyementioning
confidence: 96%